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The impact of early-diagnosed new-onset post-transplantation
diabetes mellitus (PTDM) on cardiovascular (CV) disease is
not well described. The objectives of the present prospective
single-center observational study were to assess the long-term
effects of early-diagnosed new-onset PTDM on major cardiac
events (MCE; cardiac death or nonfatal acute myocardial
infarction) and patient survival. Diabetic status and CV risk
factors were assessed in 201 consecutive renal allograft
recipients 3 months after transplantation (baseline) during a
period of 16 months (1995–96). Follow-up data until January
1, 2004 were obtained from the Norwegian Renal Registry.
The 8-year (range 7–9 years) cumulative incidence of MCEs
was 7% (nine out of 138) in recipients without diabetes, 20%
(seven out of 35) in patients with new-onset PTDM and 21%
(six out of 28) in patients with diabetes mellitus before
transplantation (DM). Proportional hazards regression
analyses (forward stepwise regression) revealed that patients
with PTDM had an approximately three-fold increased risk of
MCEs as compared with nondiabetic patients (hazard ratio
(HR)¼ 3.27, 95% confidence interval (CI)¼ 1.22–8.80,
P¼ 0.019). A total of 61 patients (30%) died. Eight-year
patient survival was 80% in the nondiabetic group, 63% in
the PTDM group and 29% in the DM group, respectively.
Pretransplant diabetes (HR¼ 5.09, 95% CI¼ 2.60–9.96,
Po0.001), age (HR¼ 1.03, 95% CI¼ 1.01–1.05, P¼ 0.016),
cytomegalovirus (CMV) infection (HR¼ 2.66, 95%
CI¼ 1.27–5.53, P¼ 0.009), and creatinine clearance (HR¼ 0.98,
95% CI¼ 0.96–1.00, P¼ 0.046), but not PTDM (HR¼ 1.20, 95%
CI¼ 0.58–2.49, P¼ 0.621), were independent predictors of
death in the multiple Cox regression model. Early-diagnosed
PTDM is a predictor of MCEs, but not of all-cause mortality,
the first 8 years after renal transplantation.
Kidney International (2006) 69, 588–595. doi:10.1038/sj.ki.5000116;
published online 4 January 2006
KEYWORDS: diabetes mellitus; kidney transplantation; cardiovascular
disease; death; C-reactive protein
Diabetes mellitus (DM) is a heterogeneous group of
metabolic disorders characterized by chronic hyperglycemia,
and diabetes is associated with increased risk of micro- and
macrovascular complications.1 The strong relation between
diabetes and cardiovascular (CV) disease (CVD) has been
explained by a variety of mechanisms, including the
detrimental effects of high fasting or postprandial blood
glucose levels,2–6 insulin resistance,7 dyslipidemia, hyper-
tension, or a combination of these risk factors (metabolic
syndrome)8 on the vasculature.
It is well known that renal transplant recipients are at high
risk of ischemic heart disease (IHD),9–11 and patients with
diabetes mellitus before renal transplantation (DM) carry an
additionally two- to four-fold higher risk of CVD9–12 and
major cardiac events (MCEs)13 as compared with nondiabetic
recipients.
During the last decade, new-onset post-transplantation
diabetes mellitus (PTDM) has been recognized as a serious
complication after renal transplantation.14–16 New-onset PTDM
may be provoked by immunosuppressive drugs (glucocorti-
coids and calcineurin inhibitors), but also shares several
features with type 2 diabetes, as both insulin resistance and
relative insulin deficiency are involved in the pathogenesis.17,18
The question whether PTDM is associated with increased
risk of CVD has been the subject of some debate. A number
of studies indicate that PTDM is associated with reduced
patient survival19–21 or increased risk of CVD.10,12,22,23 In
contrast, a large retrospective study including 1.811 renal
transplant recipients followed for a mean of 8 years reported
a similar proportion of CV deaths in patients with PTDM
(54%) and nondiabetic controls (49%).19 A small case–-
control study reported similar long-term patient survival
(mean 9 years) in PTDM patients and nondiabetic controls.24
Further, although hyperglycemia improves after tapering of
immunosuppressive therapy in a substantial number of
patients with new-onset PTDM,25 it remains unknown
whether resolution of PTDM is associated with reduced
CV risk.26
Previous studies addressing the effects of PTDM on CVD
were hampered by retrospective designs.10,12,19–22,24 In
addition, the criteria for the diagnosis of PTDM have not
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been consistently defined. Most reports define PTDM to be
present in recipients with no history of diabetes before
transplantation, but who are subsequently treated with
insulin or oral hypoglycemic agents after transplantation.14,21
Others have used self-reported diabetes20,22 or random blood
glucose values14,21 to identify patients with PTDM.
To our knowledge, no previous study has addressed
the impact of early-diagnosed new-onset PTDM (World
Health Organization/American Diabetes Association (ADA)
criteria)27,28 on CVD.
Thus, the objectives of the present 8-year prospective
single-center observational study were to assess the long-term
effects of early-diagnosed new-onset PTDM on the cumula-
tive incidence of MCEs (cardiac death or nonfatal acute
myocardial infarctions) and patient survival.
RESULTS
Baseline characteristics and risk factors
Baseline traditional and transplantation-related CV risk
factors in the three groups of patients are shown in Table 1.
Diabetic (DM and PTDM) recipients were on average 7–8
years older than nondiabetic patients, and the prevalence of
pretransplant CVD was significantly higher in the DM group
than in the nondiabetic group (P¼ 0.013). The proportion of
patients with left ventricular hypertrophy was significantly
higher in the DM group than in both the nondiabetic group
(P¼ 0.001) and the PTDM group (P¼ 0.037). The PTDM
patients had a significantly higher incidence of CMV
infection than nondiabetic patients (P¼ 0.001), whereas no
significant difference was found between the two diabetic
groups (P¼ 0.096).
Only eight patients received a statin at baseline (4%): five
out of 138 nondiabetic patients, one out of 35 PTDM
patients and two out of 28 DM patients (no significant
differences between groups).
Nine out of 35 patients (26%) with PTDM required
hypoglycemic drug therapy; six patients were treated with
insulin and three with oral hypoglycemic agents. A total of
14 PTDM patients had a normal fasting serum glucose
(o5.6 mmol/l; n¼ 7) or impaired fasting glucose (5.6–
6.9 mmol/l; n¼ 7). Thus, the diagnosis of PTDM in these
patients was based on the oral glucose tolerance test
(OGTT)-derived 2-h blood glucose concentration.
Metabolic risk factors
The patients with PTDM were on average significantly more
insulin resistant, and had lower high-density lipoprotein-
cholesterol levels, higher triglyceride concentrations and a
higher median glycosylated hemoglobin than nondiabetic
controls (Table 2).
Major cardiac events
The 8-year cumulative incidence of MCEs was 11% (22 out
of 201); 7% in recipients without diabetes (nine out of 138),
20% in patients with new-onset PTDM (seven out of 35) and
21% in patients with DM (six out of 28), respectively. The
Kaplan–Meier estimates of recipients free of cardiac events in
the three groups are shown in Figure 1.
Univariate Cox regression analyses revealed that patients
with PTDM and DM had a three- to five-fold increased risk
of an MCE as compared with nondiabetic patients
(HR¼ 3.49, 95% CI¼ 1.30–9.37, P¼ 0.013 and HR¼ 5.13,
95% CI¼ 1.81–14.58, P¼ 0.002, respectively). Other vari-
ables associated with increased risk of an MCE in the
univariate analyses were pretransplant CVD (Po0.001),
older age (P¼ 0.003), male gender (P¼ 0.038), rejection(s)
(P¼ 0.023), left ventricular hypertrophy (P¼ 0.029), and
CMV infection (P¼ 0.041). Neither daily dose of predniso-
lone nor statin therapy was associated with MCEs (data not
shown).
Table 1 | Traditional and transplantation-related cardiovascular risk factors at baseline (3 months after transplantation)
(n=201)
No diabetes
(n=138)
New-onset
PTDM (n=35)
Pretransplant
diabetes (n=28) P
Traditional risk factors
Age (years) 46 (16) 54 (15) 53 (13) 0.002
Male gender 98 (71%) 22 (63%) 19 (68%) 0.639
Pretransplant cardiovascular disease 21 (15%) 7 (20%) 10 (36%) 0.045
Weight (kg) 69 (62–79) 72 (58–86) 71 (63–79) 0.792
Smokers (yes) 29 (21%) 11 (31%) 8 (35%) 0.209
Hypertension after transplantation 113 (83%) 31 (89%) 22 (82%) 0.660
Left ventricular hypertrophy (yes) 26 (19%) 8 (24%) 12 (50%) 0.005
Transplantation-related risk factors
Cadaveric donor 78 (57%) 26 (74%) 17 (61%) 0.159
First transplant 117 (85%) 31 (89%) 23 (82%) 0.798
Acute rejection(s) (yes; X1) 74 (54%) 24 (69%) 21 (75%) 0.051
Prednisolone (mg/day) 10 (10–20) 15 (10–25) 10 (10–15) 0.092
Creatinine clearance (ml/min) 55 (45–71) 51 (41–67) 48 (38–63) 0.161
Creatinine (mmol/l) 138 (118–160) 131 (109–168) 147 (117–171) 0.673
Cytomegalovirus infection 78 (57%) 30 (88%) 20 (71%) 0.002
Values are given as mean (standard deviation (s.d.)), median (interquartile range) or numbers of patients (%). Statistics: ANOVA, Kruskal–Wallis, w2 or Fisher’s exact test as
appropriate.
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Variables significantly associated (Po0.05) with MCEs in
the univariate analyses were included in the forward stepwise
regression analyses. After retaining pretransplant CVD in the
forward regression model, only PTDM remained associated
with a significant three-fold increased risk of an MCE
(Table 3).
Overall mortality
A total of 61 recipients (30%) died during the 8-year follow-
up (Table 4). All-cause mortality rates were significantly
higher in the patients with DM (71%) than in those with
PTDM (37%) (P¼ 0.007). Both diabetes groups had
significantly higher mortality rates than the nondiabetic
group (20%) (Po0.001 and 0.036, respectively). Kaplan–-
Meier estimates of patient survival comparing patients with
either types of diabetes and nondiabetic patients are shown in
Figure 2.
Univariate Cox regression analysis revealed that patients
with PTDM and DM had a two- to five-fold increased risk of
death as compared with nondiabetic patients (HR¼ 2.11,
95% CI¼ 1.09–4.09, P¼ 0.026 and HR¼ 5.48, 95% CI¼
3.06–9.82, Po0.001, respectively). Other variables signifi-
cantly associated with increased mortality risk in univariate
analyses were older age (Po0.001), lower creatinine clearance
(Po0.001), pretransplant CVD (P¼ 0.001), CMV infection
(P¼ 0.001) and left ventricular hypertrophy (P¼ 0.015).
Daily dose of prednisolone did not influence the all-cause
mortality significantly (data not shown).
After retaining age, CMV infection and creatinine
clearance in the regression model, DM, but not PTDM,
remained associated with a significant five-fold increased all-
cause mortality risk (Table 3).
Cause of death
The major causes of death were CVD (48% of total) and
malignancy (26% of total) (Table 4). Patients with DM had a
significantly higher cumulative incidence of both CV- and
infection-related death, than the nondiabetic group (both
Po0.001). On average, a trend towards a higher incidence of
CV deaths was observed in the DM group as compared with
the PTDM group (P¼ 0.092), and in the PTDM group as
compared with the nondiabetic group (P¼ 0.058) (Table 4).
Metabolic CV risk factors and high-sensitivity C-reactive
protein; patients with PTDM compared with nondiabetic
patients
Metabolic baseline risk factors were prospectively registered
in all patients without DM (Table 2), and the potentially
confounding effects of these parameters on survival and
MCEs were addressed.
Table 2 | Metabolic cardiovascular risk factors and hsCRP at
baseline (3 months after transplantation) (n=173)
No diabetes
(n=138)
New-onset
PTDM (n=35) P
Insulin sensitivity index 7.88 (2.37) 5.35 (2.01) o0.001
Fasting blood glucose
(mmol/l)
5.4 (5.0–5.7) 6.6 (5.9–7.9) o0.001
2-h blood glucose
(mmol/l)
7.0 (6.0–8.1) 13.4 (11.3–15.3) o0.001
HbA1c (%) 5.2 (4.8–5.6) 5.5 (4.9–6.2) 0.044
Total cholesterol
(mmol/l)
6.5 (5.8–7.4) 6.8 (5.7–7.5) 0.789
Triglycerides (mmol/l) 1.8 (1.4–2.3) 2.3 (1.7–3.6) 0.017
HDL-cholesterol
(mmol/l)
1.4 (1.2–1.7) 1.3 (0.9–1.7) 0.028
LDL-cholesterol
(mmol/l)
4.1 (3.4–5.0) 4.4 (3.5–5.1) 0.623
Apo-A1 (g/l) 1.4 (1.3–1.6) 1.4 (1.1–1.6) 0.340
Apo-B (g/l) 1.2 (1.0–1.4) 1.3 (1.1–1.4) 0.166
Apo-B/Apo-A ratio 0.85 (0.68–1.00) 0.91 (0.75–1.17) 0.142
Homocysteine (mmol/l) 24 (19–33) 30 (20–38) 0.281
Lp (a) (mg/l) 94 (41–273) 68 (26–201) 0.190
hsCRP (mg/l) 0.72 (0.24–1.56) 1.63 (0.45–3.91) 0.008
Values are given as mean (SD), median (interquartile range) or numbers of patients
(%). Statistics: independent t-test, Mann–Whitney, w2 or Fisher’s exact test as
appropriate.
Table 3 | HRs of MCE (cardiac death or nonfatal myocardial
infarction) and death in patients with new-onset PTDM or
pretransplant DM as compared with no-diabetic patients
during the period 3 months to 8 years (9878 months) after
renal transplantation
Major cardiac events All-cause mortality
HR 95% CI P HR 95% CI P
PTDM 3.27 1.22–8.80 0.019 1.20 0.58–2.49 0.621
Pretransplant diabetes 2.55 0.80–8.14 0.114 5.09 2.60–9.96 o0.001
Pretransplant CVD 5.23 2.09–13.07 o0.001 NE NE NE
Age NE NE NE 1.03 1.01–1.05 0.016
CMV infection NE NE NE 2.66 1.27–5.53 0.009
Creatinine clearance NA NA NA 0.98 0.96–1.00 0.046
The results of proportional hazards regression analyses are shown. Variables
associated with MCEs and death in the univariate analyses, diabetic status,
pretransplant CVD, age, left ventricular hypertrophy and CMV infection, were
included in the regression analyses for both models. In addition, rejection and
gender were included in the analyses for the MCE model, and creatinine clearance in
the all-cause mortality model. NA, not addressed; NE, not in the equation.
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Figure 1 | Kaplan–Meier estimates of renal transplant recipients
free of cardiac events in the three different groups.
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Univariate analysis revealed that high-density lipoprotein-
cholesterol was associated with lower risk (HR¼ 0.15, 95%
CI¼ 0.04–0.56, P¼ 0.004) and apolipoprotein B/apolipo-
protein A ratio with higher risk (HR¼ 4.32, 95% CI¼
1.20–15.54, P¼ 0.025) of MCEs. Other metabolic risk factors
were not significantly associated with MCEs (data not shown).
Patients with high-sensitivity C-reactive protein (hsCRP)
in the upper quartile had a significantly higher risk of death
(HR¼ 3.08, 95% CI¼ 1.27–7.44, P¼ 0.013), but not of
MCEs (HR¼ 3.10, 95% CI¼ 0.80–12.07, P¼ 0.102), as
compared with the patients in the lower hsCRP quartile.
However, the association between hsCRP and death lost
significance in the multiple regression model (data not
shown).
PTDM and pretransplant CVD remained independent
predictors of MCEs (HR¼ 3.63, 95% CI¼ 1.35–9.77, P¼
0.011, and HR¼ 4.53, 95% CI¼ 1.62–12.63 and P¼ 0.004,
respectively) after forward stepwise regression analysis.
Univariate Cox regression analyses did not reveal any
significant association between metabolic risk factors and all-
cause mortality (data not shown).
DISCUSSION
This 8-year prospective observational study indicates that
new-onset PTDM (World Health Organization/American
Diabetes Association criteria) diagnosed during the early
post-transplant period (o3 months) is a predictor of future
myocardial infarction and cardiac death.
Comparison with other studies
Previous reports have suggested that new-onset PTDM is
associated with lower patient survival19–21 and increased
frequency of IHD.10,22,23 These studies, however, were limited
by retrospective designs, varying criteria for diagnosis of
PTDM or inclusion of patients developing PTDM up till
several years after transplantation.
This study differs from others by its prospective inclusion
of adult patients transplanted at a single national center
during a relatively short period of time (16 months), a long-
term follow-up period (8 years), and no included patients
being lost to follow-up.
Nonetheless, our results are in accordance with previous
studies, suggesting that PTDM is associated with an up to
three-fold increased risk of myocardial infarction, IHD or
CVD, 3–7 years after renal transplantation.10,12,22,23
We were unable to confirm recently published studies
suggesting that C-reactive protein is an independent risk
factor of atherosclerotic events23 and death29 in renal
transplant recipients. Although hsCRP was associated with
increased all-cause mortality in the univariate analysis,
this association lost significance in the multiple regression
model in our study. Moreover, hsCRP was not significantly
associated with MCEs. Importantly, the present study was
neither designed nor powered to specifically address the
potentially detrimental effects of hsCRP on outcomes.
New-onset PTDM vs diabetes before transplantation
Although DM was not documented to be an independent
predictor of MCEs in the present study, this may partly be
explained by a significantly higher prevalence of pretrans-
plant CVD in the DM group than in nondiabetic patients
(Tables 1 and 3). The proportion of patients who suffered an
MCE was similar in patients with DM and PTDM (21 and
20%, respectively), and the incidence of CV death tended to
be higher in DM patients than in PTDM patients (39 and
20%, respectively). Thus, our data are not in conflict with the
notion that the relative risk of CV events in patients with
PTDM and DM may be comparable. This view is in line with
a previous report showing that both patients with PTDM and
DM had a three-fold increased risk of atherosclerotic CVD
Table 4 | All cause mortality beyond 3 months after transplantation according to diabetic status
Total (n=201)
No diabetes
(n=138)
New-onset
PTDM (n=35)
Pretransplant
diabetes (n=28) P
Death total (% of patients) 61 (30%) 28 (20%) 13 (37%) 20 (71%) o0.001
Cause of death (% of patients)
Cardiovascular 29 (14%) 11 (8%) 7 (20%) 11 (39%) o0.001
Infection 11 (5%) 3 (2%) 2 (6%) 6 (21%) 0.001
Malignancy 16 (8%) 11 (8%) 4 (11%) 1 (4%) 0.562
Other/unknown 5 (2%) 3 (2%) 0 (0%) 2 (7%) 0.241
Pearson w2 or Fisher’s exact test as appropriate.
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Figure 2 | Kaplan–Meier estimates of patient survival in the three
different groups of renal transplant recipients.
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during the first 2 years after transplantation,12 and a recent
large-scale registry-based study suggesting that both PTDM
and DM are independent predictors of post-transplant
myocardial infarction.22 In the latter study, the relative risk
of myocardial infarction was actually higher in patients with
PTDM (relative risk¼ 1.6) than in patients with either
pretransplant diabetes as a comorbidity (relative risk¼ 1.1)
or recipients with diabetic nephropathy (relative risk¼ 1.4).22
On the other hand, all-cause mortality was significantly
higher in DM than in PTDM patients (71 vs 37%). This
may be explained by a tendency towards higher frequencies
of death related to CVD and infections in patients with
DM (Table 4). The average annual mortality rate of 8.9%
in DM patients seems high, but is comparable with the
results from a previous 5-year follow-up study reporting
a mortality rate of 7.2%/year in a group of patients with
either PTDM or DM.11 Importantly, all diabetic patients in
the present study were carefully examined for CV disease
before transplant, including cycle ergometer exercise testing,
and the majority also underwent coronary angiography
pretransplant.
Insulin resistance
Insulin resistance has been associated with CVD in the
general population,7 and a recent Japanese report suggests
that insulin resistance may be an independent predictor of
CV mortality in patients with end-stage renal disease.30
However, we did not confirm any significant relation between
insulin resistance and MCEs in renal transplant recipients.
Although it may be difficult to explain this apparent
discrepancy, the study populations are clearly different
(Asian vs Caucasian), and, importantly, patients in chronic
dialysis seem to be more insulin resistant than transplanted
patients with adequate renal function.31,32
Dyslipidemia
Increased low-density lipoprotein-cholesterol is an esta-
blished risk factor for IHD in renal transplant recipients33
and it has also been suggested that dyslipidemia,22 and more
specifically low high-density lipoprotein-cholesterol,10,11,13
predicts IHD in renal transplant recipients. Although high-
density lipoprotein-cholesterol and apolipoprotein B/apo-
lipoprotein A ratio were associated with MCEs in the
univariate analyses, this relationship lost significance in the
multiple regression model.
Transient vs persistent PTDM
Whether resolution of PTDM is associated with reduced risk
of CVD is unclear.26 As previously reported from our cohort,
12 out of 23 patients with early new-onset PTDM had
transient PTDM according to a repeated normalized OGTT 1
year later.25 Interestingly, a post hoc analysis of these data
revealed that no MCE occurred in the group of 12 patients
with transient PTDM, as compared to four MCEs in the
group of 11 patients with persistent PTDM (P¼ 0.037).
Obviously, this finding needs verification, but it indicates that
repeated OGTTs in patients with early-diagnosed PTDM may
be of clinical importance.
Limitations
Our study has limitations. First, the unexpected relatively low
number of events reduced the power of detecting the
potential adverse effect of PTDM on predefined study end
points. The average annual mortality rate was lower than
reported in a previous Norwegian study (annual mortality
3.8 vs 4.3%),11 which may be explained by the generally
observed improved survival in renal transplant recipients
during the last two decades.34
Second, the diagnosis of PTDM was made in the early
post-transplant period of high corticosteroid exposure, and
the results may not have relevance for transplant patients not
receiving steroids or recipients on steroid-sparing immuno-
suppressive regimens. In addition, the majority of patients
were Caucasian, and our results may not be generalized to
non-Caucasian transplant populations.
Finally, new-onset PTDM was associated with increased
mortality in the univariate analysis, but did not predict death
after adjustment for confounding factors. This is in contrast
with findings from some previous studies,19–21 but in
agreement with others.24,35 Of note, the apparent lack of
relationship between PTDM and mortality in the latter24,35
and present studies may be due to limited sample size (type II
error). More specifically, the present study was not powered
to detect a less than two-fold increased risk of all-cause death.
A larger number of patients and/or a longer time of follow-
up are probably necessary to establish any independent effect
of early-diagnosed new-onset PTDM on patient survival.
Consequences for clinical practice
Some risk factors associated with cardiac events are
irremediable: the most important of them are age and
gender. The potential remediable risk factors for cardiac
outcomes in transplant recipients are smoking, dyslipidemia,
hypertension and obesity, among others. Only one CV
intervention study has been performed in renal transplant
recipients; demonstrating that lowering of low-density
lipoprotein-cholesterol resulted in reduction of cardiac
events.33 Our study indicates that strategies to limit the
development of diabetes after renal transplantation may also
have a beneficial effect on the incidence of future cardiac
events. Clearly, this hypothesis needs further study.
Conclusions
Early-diagnosed new-onset PTDM is a predictor of MCEs the
first 8 years after renal transplantation. An OGTT in the early
post-transplant period may represent a simple and valuable
method to screen and detect renal allograft recipients deve-
loping this potentially serious post-transplant complication.
MATERIALS AND METHODS
From a total of 237 patients who received a kidney allograft between
February 20, 1995 and June 17, 1996 at Rikshospitalet University
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Hospital, 36 patients were excluded due to early (o3 months after
the day of transplantation) death, graft loss, referral to local
hospitals, or age o18 years. The remaining 201 patients, most of
whom were Caucasian (n¼ 193), were eligible for inclusion at
baseline, 3 months after transplantation (Figure 3).
The study was approved by the local ethics committee and was
performed in accordance with the Declaration of Helsinki
Principles.36 The study population, the immunosuppressive proto-
col and laboratory analyses have been described in detail.16,25,37
A total of 35 out of 173 individuals with no medical history of
diabetes before transplantation developed new-onset PTDM,
whereas 138 patients remained nondiabetic at baseline (Figure 3).37
All patients specifically confirmed the absence of pretransplant
diabetes by completing a questionnaire addressing this and other
issues (see below). In addition, pretransplant nondiabetic status was
verified by at least one fasting pretransplant blood glucose
concentration in the majority of the patients (83%) and an
OGTT in half of the patients (n¼ 86). On average, patients
developing PTDM had significantly higher fasting pretransplant
blood glucose levels than those remaining nondiabetic (5.370.8 and
4.970.6 mmol/l, respectively, P¼ 0.030).
All patients (n¼ 201) received prednisolone, the majority were
treated with cyclosporine A (n¼ 193) and only five patients received
tacrolimus. New-onset PTDM was diagnosed according to current
guidelines;27,28,38 fasting serum glucose X7.0 mmol/l or 2-h serum
glucose X11.1 mmol/l. An OGTT was performed 10 weeks after
transplantation in 167 out of 173 recipients who had no history of
diabetes before transplantation. The remaining six patients devel-
oped manifest PTDM and required treatment with insulin (n¼ 5) or
oral hypoglycemic drugs (n¼ 1) during the first week. These
patients did not undergo the OGTT procedure, but were included in
the analyses.
Patients with DM before transplantation
A total of 13 patients had type 1 diabetes, and 15 patients had
type 2 diabetes. The patients with DM before transplantation were
included as one of three groups in the statistical analyses. Five type 1
patients received a combined kidney and pancreas allograft. Diabetic
nephropathy was the cause of end-stage renal disease in all patients
with type 1 diabetes and in four (27%) of the recipients with type 2
diabetes.
Baseline CV risk factors, including signs and symptoms of
pretransplant CVD
Patients without pretransplant diabetes completed a questionnaire
addressing pretransplant diabetic status, smoking habits and present
or pretransplant symptoms of CVD (angina pectoris, intermittent
claudication).37 All medical records were reviewed with respect to
the presence of pretransplant CVD (myocardial infarction, coronary
artery bypass grafting, percutaneous transluminal coronary angio-
plasty, significant stenoses revealed by coronary angiography, aortic
aneurysm or cerebrovascular events). In addition, several metabolic
risk factors were prospectively analyzed and registered in the 173
patients without diabetes before transplantation.37
Major baseline risk factors such as age, gender, pretransplant
CVD, rejections and CMV infection were carefully obtained from
patient records also in patients with DM, whereas metabolic
parameters were not systematically registered in this group of
patients.
Electrocardiograms were recorded on the day of transplantation.
Left ventricular hypertrophy was diagnosed according to the
Sokolow–Lyon criteria. Patients with repeated blood pressure
values in the sitting or recumbent position above systolic 140 mmHg
or diastolic 90 mmHg and those treated with antihypertensive
medication were classified as hypertensive.
Insulin sensitivity
The OGTT-derived insulin sensitivity index (ISI) modified from
Stumvoll et al.39,40 was used to estimate the insulin sensitivity:
ISITX¼ 0.208–0.0032BMI–0.0000645Ins120–0.00375Gluc120, where Ins120
and Gluc120 are serum insulin and glucose values at 120 min.
Screening for CMV infection
Patients were screened for CMV infection the first 3 months after
transplantation by repeated measurements of CMV phosphoprotein
65 (pp65) lower matrix protein in ethylene diamine tetraacetate
blood samples. The assay for CMV pp65 antigen was performed as
described previously.41 CMV infection was diagnosed in patients
who had at least one positive CMV pp65 antigenemia test (X1
CMV pp65 positive cells per 100 000 leukocytes) during the first 3
months after transplantation.42,43
High-sensitivity C-reactive protein
hsCRP was measured as described by others.44 Briefly, wells were
coated overnight with polyclonal rabbit anti-human C-reactive
protein antibody (A0073; 10 mg/l in sterile phosphate-buffered
saline). The standard was delipidated, pooled human serum
enriched in C-reactive protein (X 0923), 0.16–40 mg/l. Subsequent
steps included rabbit anti-human C-reactive protein/HRP antibody
(P0227, 1:3000) and tetramethylbenzidine as substrate (Zymed
Laboratories, San Francisco, CA, USA). The assay buffer was 1%
bovine serum albumin in phosphate-buffered saline. All antibodies
and standard were from DakoCytomation, Glostrup, Denmark.
Outcomes; definitions and assessment
Endpoint data were collected from the Norwegian Renal Registry.
This registry is based upon annual reports from nephrologists at
19 centers, and includes all Norwegian patients on renal replacement
Kidney transplant recipients (n=237)
Transplanted between Feb 20 1995 and Jun 17 1996
DM before transplantation (n=28) New-onset PTDM (n=35) No diabetes after transplantation (n=138)
Excluded (n=36)*
Figure 3 | Study design. *Early (o3 months) death (n¼ 8) or graft loss (n¼ 9), transferred to local hospitals (n¼ 11) or age o18 years (n¼ 8).
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therapy. The annual reports include detailed information on
medication, laboratory tests, immunosuppressive therapy and CV
complications. If a patient dies, the event is reported immediately.
An MCE was defined as the occurrence of a cardiac death
European Renal Association (ERA)–European Dialysis and Trans-
plant Association (EDTA) cause of death codes 11; myocardial
ischemia and infarction 15; cardiac arrest, cause unknown) or a
nonfatal acute myocardial infarction. Death was categorized
according to the ERA–EDTA causes of death codes; that is,
cardiac,11–18 vascular,21–28 infection31–42 or malignancy.66,67
Statistical analysis
Baseline characteristics for the three groups of patients (DM, PTDM
and nondiabetic) were compared by using one-way analysis of
variance or Kruskal–Wallis test (nonparametric) for continuous
data, whereas independent t-test or Mann–Whitney test (nonpara-
metric) was used for comparison of continuous data between two
different groups of patients. Proportions were analyzed by w2 test or
Fisher’s exact test as appropriate.
We used Kaplan–Meier plots (log rank test) and Cox propor-
tional hazards regression models (univariate and forward stepwise
regression) to analyze the effects of DM, PTDM and no-diabetes, on
cumulative incidence of MCEs and patient survival, respectively.
Diabetic status was included as the first variable in the regression
analyses; no-diabetes¼ 0, PTDM¼ 1 and DM¼ 2, with nondiabetic
patients as the reference group. Variables significantly associated
(Po0.05) with MCEs or death in the univariate analyses were
included in the forward stepwise regression analyses. The analyses
were implemented using SPSSs 12.0 (SPSS, Chicago, IL, USA).
In view of recently published data on the incidence of
CVD in Norwegian renal transplant recipients,11 the present study
had a power of more than 80% (a¼ 0.05) to detect a two-fold
increased 8-years risk of cardiac events and death in patients with
new-onset PTDM as compared to patients without diabetes at
baseline.45
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